Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)
PHASE2CompletedINTERVENTIONAL
Enrollment
20
Participants
Timeline
Start Date
March 31, 2016
Primary Completion Date
December 31, 2017
Study Completion Date
December 31, 2017
Conditions
IgG4-RD
Interventions
BIOLOGICAL
XmAb5871
Trial Locations (1)
02114
Massachusetts General Hospital, Boston
All Listed Sponsors
collaborator
Massachusetts General Hospital
OTHER
lead
Xencor, Inc.
INDUSTRY
NCT02725476 - Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD) | Biotech Hunter | Biotech Hunter